摘要:
The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib): (I) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.
摘要:
The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
摘要:
The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
摘要:
The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.
摘要:
The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.
摘要:
The invention encompasses a novel class of diaryl ether derivatives which inhibit the processing of APP by the putative γ-secretase while sparing Notch signaling pathway, and thus are useful in the treatment or prevention of Alzheimer's disease without the development of Notch inhibition mediated gastrointestinal issues. Pharmaceutical compositions and methods of use are also included.
摘要:
A tensioning device (10) for a seat belt, in particular in a motor vehicle, having a gas generator (17) and a piston (21) guided in a tube (16) that closes a pressure space (20) in the tube (16), whereas the pressure space (20) can be pressurized by the gas generator (17), as a result of which the piston (21) can be driven to perform a tensioning operation which can be transmitted to the seat belt by means of the force transmission means. The piston (21) having a closed or constricted opening (1, 1a), and the opening (1, 1a) can be enlarged and/or opened by the material erosion caused by the pressure and/or pressure conditions in the pressure space (20).
摘要:
According to the invention there is provided a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof; wherein the variables are as defined herein. The compounds selectively attenuate the production of Aβ42 and hence are useful in treatment of Alzheimer's disease and related conditions.
摘要:
A monolithic catalyst system for the cleavage of water into hydrogen and oxygen comprises a first photoactive material capable by itself or together with an auxiliary material and/or an auxiliary catalyst when irradiated with light having a wavelength ≧420 nm of generating oxygen and protons from water, and a second photoactive material capable by itself or together with an auxiliary material and/or an auxiliary catalyst when irradiated with light having a wavelength ≧420 nm of reducing protons in water to hydrogen. The first and second photoactive materials are in electrical contact via an electron-conducting material.
摘要:
The invention encompasses 2-[4-(imidazolyl)-phenyl]vinyl-heterocycle derivatives which selectively attenuate production of Abeta(1-42) and are useful in the treatment of Alzheimer's disease. Pharmaceutical compositions and methods of use are also encompassed.